Email this article Long-term effect of 3-week intravenous б-lipoic acid administration in symptomatic diabetic polyneutropathy with clinical manifestations
- Authors: Ametov A.S.1, Novosadova MV1, Barinov AN1, Samigullin R1, Tritschler H.1, Ametov AS2, Novosadova MV2, Barinov AN3, Samigullin R4, Tritschler H-.5
-
Affiliations:
- Russian Medical Academy of Postgraduate Education
- Pain Clinic, Marfo-Mariinsk Charity Medical Center
- Orthonica GmbH
- MEDA Pharma GmbH & Co. KG
- Issue: Vol 82, No 12 (2010)
- Pages: 61-64
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30760
- ID: 30760
Cite item
Full Text
Abstract
Subects and methods. The study included patients with symptoms of myodiabetic polyneuropathy. The authors studied trends in neuropathic symptoms by the TSS scale and neuropathic deficit by the NIS-LL scale after 3-week intravenous a-LA (600 mg/day) administration. Control follow-up visits were made at weeks 8 and 30 of the study.
Results. In б-LA-treated patients, the mean TSS score dropped from 9.46±1.01 to 3.29±1.49 after intravenous б-LA administration and continued to decrease to 2.60±1.18 and 4.39±2.01 scores at follow-up weeks 8 and 30, respectively. In the placebo group, these were 9.78±1.23, 6.16±1.95, 6.52±1.61, and 7.36±1.31 scores at weeks 3, 8, and 30, respectively; p < 0.05). In the б-LA group, NIS-LL scores fell from 8.65±3.46 to 6.01±3.12 at therapy week 3, to 6.11±3.36, at week 8, and to 7.68±3.68 at week 30 and in the placebo group, these decreased from 8.35±3.84 to 7.81±3.51, 7.89±3.72, and 8.32±3.49 scores at weeks 3, and 8, respectively; p < 0.05).
Conclusion. Alleviated neuropathic symptoms persisted within 6 months after 3-week intravenous б-LA injection. Reduced neuropathic deficit did within 8 weeks after initiation of б-LA therapy.
Keywords
About the authors
Aleksandr Sergeevich Ametov
Email: alexander.ametov@gmail.com
M V Novosadova
A N Barinov
R Samigullin
Hans-J'rgen Tritschler
A S Ametov
Russian Medical Academy of Postgraduate EducationRussian Medical Academy of Postgraduate Education
M V Novosadova
Russian Medical Academy of Postgraduate EducationRussian Medical Academy of Postgraduate Education
A N Barinov
Pain Clinic, Marfo-Mariinsk Charity Medical CenterPain Clinic, Marfo-Mariinsk Charity Medical Center
R Samigullin
Orthonica GmbHOrthonica GmbH
H -J Tritschler
MEDA Pharma GmbH & Co. KGMEDA Pharma GmbH & Co. KG
References
- MacDonald B. K., Cockerell O. C., Sander J. W., Shorvon S. D. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000; 123: 665-676.
- Ziegler D., Rathmann W., Dickhaus T. et al. for the KORA Study Group. Prevalence of polyneuropathy in prediabetes and diabetes is associated with abdominal obesity and macroangiopathy. The MONICA/KORA Augsburg Surveys S2 and S3. Diabet. Care 2007;
- Boulton A. J. M., Vinik A. I., Arezzo J. C. et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabet. Care 2005; 28: 956-962.
- Coppini D. V., Bowtell P. A., Weng C. et al. Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model. J. Clin. Epidemiol. 2000; 53: 519-523.
- Daousi C., MacFarlane I. A., Woodward A. et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet. Med. 2004; 21: 976-982.
- Davies M., Brophy S., Williams R., Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabet. Care 2006; 29: 1518-1522.
- Galer B. S., Gianas A., Jensen M. P. Painful diabetic neuropathy: epidemiology, pain description, and quality of life. Diabet. Res. Clin. Pract. 2000; 47: 123-128.
- Daousi C., Benbow S. J., Woodward A., MacFarlane I. A. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diabet. Med. 2006; 23: 1021-1024.
- Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabet. Care 2008; 31(Suppl. 2): S255-S261.
- Stracke H., Gaus W., Achenbach U. et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp. Clin. Endocrinol. Diabet. 2008;
- Ziegler D. Thioctic acid: A critical review of its effects in patients with symptomatic diabetic polyneuropathy. Treat. Endocrinol. 2004; 3: 173-189.
- Vincent A. M., Russell J. W., Low P., Feldman E. L. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr. Rev. 2004; 25: 612-628.
- Ziegler D., Sohr C. G. H., Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and autonomic neuropathy. Diabet. Care 2004; 27: 2178-2183.
- Ziegler D., Nowak H., Kempler P. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant б-lipoic acid: a meta-analysis. Diabet. Med. 2004; 21: 114-121.
- Ametov A., Barinov A., O'Brien P. et al. The sensory symptoms of diabetic polyneuropathy are improved with б-lipoic acid. The SYDNEY Trial. Diabet. Care 2003; 26: 770-776.
- Dworkin R. H., Turk D. C., Wyrwich K. W. et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT Recommendations. J. Pain 2008; 9: 105-121.
- Ziegler D., Ametov A., Barinov A. et al. Oral treatment with б-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 Trial. Diabet. Care 2006; 29: 2365-2370.
- Ziegler D., Low P. A., Boulton A. J. M. et al. Antioxidant treatment with б-lipoic acid in diabetic polyneuropathy. A 4-year randomised double-blind trial (NATHAN 1 Study). Diabetologia 2007; 50 (Suppl. 1): S 63.
Supplementary files
